Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
25 May 2021 10:00 AM
RNS
Posting of Annual Report and Notice of AGM
10 May 2021 10:36 AM
RNS
AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
06 May 2021 07:00 AM
RNS
Change of Nominated Adviser
30 Apr 2021 12:37 PM
RNS
Issue of Equity
28 Apr 2021 05:18 PM
RNS
Issue of Equity
28 Apr 2021 04:41 PM
RNS
Second Price Monitoring Extn
28 Apr 2021 04:36 PM
RNS
Price Monitoring Extension
22 Apr 2021 07:00 AM
RNS
Final Results
20 Apr 2021 11:05 AM
RNS
Second Price Monitoring Extn
20 Apr 2021 11:00 AM
RNS
Price Monitoring Extension
20 Apr 2021 07:00 AM
RNS
Clinical validation of AffiDX Lateral Flow Test
15 Apr 2021 04:36 PM
RNS
Price Monitoring Extension
13 Apr 2021 07:00 AM
RNS
Notice of Results and Investor Presentation
12 Apr 2021 01:30 PM
RNS
Issue of Equity
06 Apr 2021 07:00 AM
RNS
Distribution Agreement with ABCAM plc
25 Mar 2021 03:01 PM
RNS
Directorate Change
16 Mar 2021 05:08 PM
RNS
Issue of Equity
15 Mar 2021 05:22 PM
RNS
Issue of Equity
09 Mar 2021 07:00 AM
RNS
Diagnostic Licensing Deal with Biokit
08 Mar 2021 07:00 AM
RNS
Rapid Antigen Test Detects SARS-CoV-2 Variants
03 Mar 2021 05:14 PM
RNS
Electronic Communications with Shareholders
24 Feb 2021 07:00 AM
RNS
Business Update
22 Feb 2021 07:00 AM
RNS
Re: Press Speculation
18 Feb 2021 07:00 AM
RNS
Phase I CTA for AVA6000 Approved by MHRA
16 Feb 2021 09:05 AM
RNS
Second Price Monitoring Extn
16 Feb 2021 09:00 AM
RNS
Price Monitoring Extension
16 Feb 2021 07:00 AM
RNS
Results of Initial Evaluation of SARS-CoV-2 LFT
08 Feb 2021 07:00 AM
RNS
Commercial Partnership with Mologic
02 Feb 2021 08:30 AM
RNS
Issue of Equity
01 Feb 2021 07:00 AM
RNS
AffyXell $7.3 Million Series A Financing
29 Jan 2021 11:00 AM
RNS
Issue of Equity
28 Jan 2021 07:00 AM
RNS
Collaboration Agreement with Bruker
07 Jan 2021 07:00 AM
RNS
License Agreement with POINT Biopharma Inc.
05 Jan 2021 11:05 AM
RNS
Second Price Monitoring Extn
05 Jan 2021 11:00 AM
RNS
Price Monitoring Extension
23 Dec 2020 07:00 AM
RNS
Submission of CTA for AVA6000 Pro-doxorubixin
21 Dec 2020 07:00 AM
RNS
License Agreement with Astrea Bioseparations
23 Nov 2020 09:05 AM
RNS
Second Price Monitoring Extn
23 Nov 2020 09:00 AM
RNS
Price Monitoring Extension
23 Nov 2020 07:00 AM
RNS
SARS-CoV-2 Rapid Antigen Test Update
18 Nov 2020 04:40 PM
RNS
Second Price Monitoring Extn
18 Nov 2020 04:36 PM
RNS
Price Monitoring Extension
13 Nov 2020 02:15 PM
RNS
Issue of Equity
10 Nov 2020 11:06 AM
RNS
Second Price Monitoring Extn
10 Nov 2020 11:00 AM
RNS
Price Monitoring Extension
09 Nov 2020 02:06 PM
RNS
Second Price Monitoring Extn
09 Nov 2020 02:01 PM
RNS
Price Monitoring Extension
22 Oct 2020 01:50 PM
RNS
Director/PDMR Shareholding
08 Oct 2020 09:00 AM
RNS
Issue of Equity
30 Sep 2020 02:05 PM
RNS
Second Price Monitoring Extn

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100